Biomarkers play a vital role in disease detection and treatment follow-up. It is important to note that the diseases in the early stage are typically treated with the greatest probability of success. Therefore, the early detection of biomarkers is very important in the case of cancer, cardiovascular disorders, and other pathological conditions. Biomarkers may includes antigens, DNA, mRNA, and enzymes. Cardiac biomarkers are part of the standards of care and guidelines for myocardial infarction and heart failure. Cardiac biomarkers represent also an evolving field of innovations to improve the prevention, diagnosis and monitoring of cardiovascular disorders. The ultimate goal behind the use of biomarkers for diagnosis is to develop reliable and cost-effective powerful detection tools for early diagnosis of diseases and disorders. A serial combination testing of a sensitive early marker (e.g., H-FABP, myoglobin, or CK-MB isoforms) and one of the cardiac-specific troponins (cTnT or cTnI) offers the best approach. Identifying the needs of physicians and potential new candidates for routine requires both multidisciplinary exchanges and translational research. Data mining and machine learning offer now more possibilities for this quest. Laboratorians play a key role after that to implement new biomarkers in routine practices and check the performances according to practices and accreditation specifications. Education and its continuing cycle is glue for an efficient integration in clinical practices and appropriate use by health care professionals. Thus, biomarker detection platforms must therefore be adapted for a rapid and sensitive point-of-care testing.
1. Describe the value of cardiac biomarkers in emergency settings
2. Artificial Intelligence (AI) and its applications in cardiovascular early risk prediction
3. Present the needs for training and continuing education of health care professionals